RKDA · Arcadia Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.10M | - | $1.30M | $1.46M | $1.20M | - | $1.54M | $1.31M | $1.25M | - |
| Cost of Revenue | $700.0K | - | $884.0K | $824.0K | $682.0K | - | $1.03M | $633.0K | $820.0K | - |
| Gross Profit | $400.0K | - | $418.0K | $631.0K | $518.0K | - | $505.0K | $673.0K | $435.0K | - |
| R&D | - | - | $0 | $9.0K | $0 | - | $24.0K | $10.0K | $272.0K | - |
| SG&A | $1.18M | - | $1.57M | $2.12M | $1.74M | - | $2.24M | $2.68M | $3.19M | - |
| Total Operating Expenses | $1.88M | - | $2.45M | $1.96M | $670.0K | - | $3.30M | ($674.0K) | $4.32M | - |
| D&A | $8.0K | - | $2.0K | $15.0K | $13.0K | - | $7.0K | $17.0K | $51.0K | - |
| Operating Income | ($779.0K) | - | ($1.15M) | ($501.0K) | $530.0K | - | ($1.76M) | $1.98M | ($3.06M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | $0 | $0 | - | - |
| Net Income | ($4.38M) | - | $856.0K | ($4.46M) | $2.60M | - | ($1.61M) | $1.06M | ($2.42M) | - |
| EPS - Basic | ($2.11) | - | $0.63 | ($3.26) | $1.90 | - | ($1.18) | $0.78 | ($1.78) | - |
| EPS - Diluted | ($2.11) | - | $0.62 | ($3.26) | $1.90 | - | ($1.18) | $0.78 | ($1.78) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $954.0K | $259.0K | $1.12M | $1.38M | $3.16M | $4.24M | $3.94M | $5.50M | $3.32M | $6.52M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $840.0K | $1.21M | $1.46M | $1.49M | $1.28M | $904.0K | $835.0K | $978.0K | $1.83M | $1.96M |
| Accounts Payable | - | $1.45M | - | - | - | $703.0K | - | - | - | $801.0K |
| Current Assets | $5.17M | $6.36M | $8.39M | $7.58M | $8.85M | $9.24M | $10.71M | $12.43M | $11.64M | $14.97M |
| Total Assets | $5.32M | $6.55M | $8.58M | $7.79M | $12.99M | $13.52M | $15.24M | $17.37M | $16.05M | $19.70M |
| Current Liabilities | $1.36M | $2.06M | $2.29M | $1.84M | $2.22M | $2.56M | $2.33M | $2.70M | $2.88M | $3.59M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $2.44M | $2.41M | $3.14M | $3.25M | $4.08M | $7.29M | $5.09M | $5.80M | $5.56M | $7.00M |
| Stockholders' Equity | $2.88M | $4.14M | $5.44M | $4.53M | $8.90M | $6.22M | $10.29M | $11.70M | $10.62M | $12.84M |
| Retained Earnings | ($285.60M) | ($281.22M) | ($279.88M) | ($280.74M) | ($276.28M) | ($278.88M) | ($274.81M) | ($273.20M) | ($274.26M) | ($271.84M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.10M) | - | - | - | ($1.59M) | - | - | - | ($3.21M) | - |
| Investing Cash Flow | $0 | - | - | - | $500.0K | - | - | - | $4.0K | - |
| Financing Cash Flow | $1.79M | - | - | - | $5.0K | - | - | - | $5.0K | - |
| CapEx | - | - | - | - | $0 | - | - | - | $13.0K | - |
| Free Cash Flow | - | - | - | - | ($1.59M) | - | - | - | ($3.22M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 36.4% | - | 32.1% | 43.4% | 43.2% | - | 32.9% | 51.5% | 34.7% | - |
| Operating margin | -70.8% | - | -88.5% | -34.4% | 44.2% | - | -114.5% | 151.6% | -244.1% | - |
| EBITDA margin | -70.1% | - | -88.3% | -33.4% | 45.3% | - | -114.1% | 152.9% | -240.1% | - |
| Net margin | -398.6% | - | 65.7% | -306.4% | 216.6% | - | -104.9% | 81.2% | -193.1% | - |
| Free cash flow margin | - | - | - | - | -132.3% | - | - | - | -256.8% | - |
| FCF / Net income | - | - | - | - | -0.61 | - | - | - | 1.33 | - |
| R&D / Revenue | - | - | 0.0% | 0.6% | 0.0% | - | 1.6% | 0.8% | 21.7% | - |
| SG&A / Revenue | 107.2% | - | 120.6% | 145.9% | 144.8% | - | 145.8% | 205.4% | 254.1% | - |
| Effective tax rate | - | - | - | - | - | - | - | 0.0% | - | - |
| Return on assets | -82.4% | - | 10.0% | -57.2% | 20.0% | - | -10.6% | 6.1% | -15.1% | - |
| Return on equity | -152.0% | - | 15.7% | -98.3% | 29.2% | - | -15.7% | 9.1% | -22.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.79 | 3.09 | 3.67 | 4.12 | 3.99 | 3.61 | 4.60 | 4.61 | 4.05 | 4.17 |
| Quick ratio | 3.17 | 2.50 | 3.03 | 3.31 | 3.41 | 3.25 | 4.24 | 4.25 | 3.41 | 3.63 |
| Cash ratio | 0.70 | 0.13 | 0.49 | 0.75 | 1.43 | 1.66 | 1.69 | 2.04 | 1.15 | 1.82 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.85 | 1.58 | 1.58 | 1.72 | 1.46 | 2.17 | 1.48 | 1.48 | 1.51 | 1.53 |
| Liabilities / Assets | 0.46 | 0.37 | 0.37 | 0.42 | 0.31 | 0.54 | 0.33 | 0.33 | 0.35 | 0.36 |
| Efficiency | ||||||||||
| Asset turnover | 0.21 | - | 0.15 | 0.19 | 0.09 | - | 0.10 | 0.08 | 0.08 | - |
| Inventory turnover | 0.83 | - | 0.61 | 0.55 | 0.53 | - | 1.24 | 0.65 | 0.45 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 438d | - | 602d | 660d | 688d | - | 295d | 564d | 815d | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | 5.6x | - | 1.6x | - | - | 4.0x | - | - |
| P / B | 1.0x | - | 0.9x | 1.3x | 0.5x | - | 0.4x | 0.4x | 0.3x | - |
| P / S | 2.6x | - | 3.7x | 4.0x | 3.4x | - | 2.4x | 3.3x | 2.4x | - |
| EV / EBITDA | - | - | - | - | 1.7x | - | - | -0.6x | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -8.3% | - | -15.3% | 11.4% | -4.4% | - | -3.8% | -6.0% | -16.8% | - |
| Revenue CAGR (3y) | -10.0% | - | -11.5% | -27.8% | -28.0% | - | -13.5% | -2.4% | 14.9% | - |
| Revenue CAGR (5y) | 5.8% | - | 32.9% | 38.9% | 31.2% | - | 33.0% | 45.1% | 42.4% | - |
| Gross profit growth (YoY) | -22.8% | - | -17.2% | -6.2% | 19.1% | - | 2.0% | 65.0% | -36.4% | - |
| Operating income growth (YoY) | - | - | 34.5% | - | - | - | 45.7% | - | 24.3% | - |
| Net income growth (YoY) | - | - | - | - | - | - | 37.2% | 28.9% | 74.2% | - |
| EPS growth (YoY) | - | - | - | - | - | - | 37.6% | 27.9% | 83.6% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | 45.6% | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | 50.7% | - | - | - | 7.0% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -67.6% | -33.5% | -47.1% | -61.3% | -16.2% | -51.5% | -33.8% | -34.5% | -36.9% | -38.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$4.86M totalProduct$4.86M · 100.0%
Geographic
$4.86M totalUS$4.86M · 100.0%
Peer comparison
Same SIC group: Crude Petroleum & Natural Gas
Comparing Arcadia Biosciences against the 5 most active filers in the same SIC group.